Arca
Skip to content
Tools
Tools

TGFB1: Transforming growth factor beta-1 proprotein

Transforming growth factor beta-1 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively. {ECO:0000269|PubMed:29109152, ECO:0000303|PubMed:27252363}.

  • Drugs that act on it: 3
  • Approved: 0
  • In phases 1 to 3: 3
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on TGFB1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 2
  • Other 1

Approved0

    Phase 30

      Phase 23

      • Fresolimumab
      • LY-2382770
      • Metelimumab

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Transforming growth factor beta-1 inhibitor.
        FresolimumabPhase 2SanofiAntibodyInhibitor0
        LY-2382770Phase 2Eli LillyOtherInhibitor0
        MetelimumabPhase 2—AntibodyInhibitor0

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Camurati-Engelmann disease0.80
        • Inflammatory bowel disease, immunodeficiency, and encephalopathy0.69
        • Coronary artery disorder0.58
        • Cancer0.53
        • Cardiovascular disorder0.53
        • Coronary atherosclerosis0.49
        • Heart disorder0.49
        • Hematuria0.49

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1795178, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01137, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.